A detailed history of National Bank Of Canada transactions in United Therapeutics Corp stock. As of the latest transaction made, National Bank Of Canada holds 162 shares of UTHR stock, worth $58,355. This represents 0.0% of its overall portfolio holdings.

Number of Shares
162
Previous 162 -0.0%
Holding current value
$58,355
Previous $58,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$311.04 - $363.55 $7,464 - $8,725
-24 Reduced 12.9%
162 $58,000
Q2 2024

Aug 02, 2024

SELL
$228.26 - $319.04 $7,532 - $10,528
-33 Reduced 15.07%
186 $59,000
Q1 2024

May 13, 2024

SELL
$210.76 - $249.51 $4.49 Million - $5.32 Million
-21,312 Reduced 98.98%
219 $50,000
Q4 2023

Feb 06, 2024

SELL
$214.88 - $256.94 $4.22 Million - $5.05 Million
-19,637 Reduced 47.7%
21,531 $4.73 Million
Q3 2023

Oct 10, 2023

BUY
$211.82 - $248.24 $5.07 Million - $5.95 Million
23,956 Added 139.18%
41,168 $9.3 Million
Q2 2023

Jul 26, 2023

BUY
$205.19 - $232.99 $2.65 Million - $3.01 Million
12,936 Added 302.53%
17,212 $3.8 Million
Q1 2023

Apr 12, 2023

BUY
$212.99 - $276.17 $867,082 - $1.12 Million
4,071 Added 1985.85%
4,276 $957,000
Q4 2022

Jan 24, 2023

SELL
$205.95 - $280.43 $765,928 - $1.04 Million
-3,719 Reduced 94.78%
205 $0
Q3 2022

Oct 13, 2022

BUY
$203.3 - $244.17 $765,221 - $919,055
3,764 Added 2352.5%
3,924 $839,000
Q2 2022

Jul 28, 2022

SELL
$174.81 - $241.14 $1.05 Million - $1.44 Million
-5,982 Reduced 97.39%
160 $38,000
Q1 2022

May 05, 2022

BUY
$166.16 - $213.96 $996,960 - $1.28 Million
6,000 Added 4225.35%
6,142 $1.1 Million
Q4 2021

Jan 24, 2022

BUY
$184.32 - $216.08 $26,173 - $30,683
142 New
142 $31,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.4B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.